Role of Different Molecular Pathways in the Development of Diabetes-Induced Nephropathy

Virvikram Sharma* and Sharma PL

Department of Pharmacology, ISF College of Pharmacy, India

Abstract

Diabetes mellitus is heterogeneous primary disorder of carbohydrate metabolism with multiple etiologic factors that generally involves absolute or relative insulin deficiency or insulin resistance or both, which results in hyperglycemia. According to WHO projection; it will be the single largest non-communicable disease worldwide by the year 2025 with the largest diabetic population in India. India leads the world with largest diabetic population thus, being termed the "Diabetes Capital of the World". However, the prevalence of diabetes is consistently increasing, but still an effective treatment is lacking for the management of this epidemic. The uncontrolled and chronic diabetes mellitus often leads to cardiomyopathy, macrovascular complications and microvascular complications that include retinopathy, neuropathy and nephropathy. Diabetic Nephropathy (DN) is mainly characterized by decreased Glomerular Filtration Rate (GFR), excessive deposition of extracellular matrix proteins, thickening of the peripheral glomerular basement membrane, glomerular hypertrophy, tubulointerstitial fibrosis, increased excretion of albumin and decreased creatinine clearance.

Keywords: Diabetes; Nephropathy; Polyol pathway; PKC pathway; Oxidative stress

Introduction

DN is a leading cause of end-stage renal failure and its morbidity and mortality is continuously increasing. Diabetic nephropathy is a clinical syndrome characterized by decreased Glomerular Filtration Rate (GFR), excessive deposition of extracellular matrix proteins [1,2] thickening of the peripheral glomerular basement membrane [3], glomerular hypertrophy, tubulointerstitial fibrosis [4], decreased excretion of albumin [5] and decreased creatinine clearance [2].

Stages of Diabetic Nephropathy

Approximately 25% to 40% of patients with DM 1 ultimately develop Diabetic Nephropathy (DN), which progresses through about five predictable stages.

Stage 1

Hyperfiltration (Glomerular hypertrophy) (very early diabetes)- Increased demand upon the kidneys is indicated by an above-normal Glomerular Filtration Rate (GFR).

Stage 2

Hyperfiltration (Mesangial expansion / basement membrane thickening (developing diabetes))- The GFR remains elevated or has returned to normal, but glomerular damage has progressed to significant microalbuminuria (small but above-normal level of the protein albumin in the urine). Patients in stage 2 excrete more than 30 mg of albumin in the urine over a 24-hour period. Significant microalbuminuria will progress to End-Stage Renal Disease (ESRD). Therefore, all diabetes patients should be screened for microalbuminuria on a routine (yearly) basis.

Stage 3

Microalbuminuria (Mesangial sclerosis) (Overt, or dipstick-positive diabetes) — Glomerular damage has progressed to clinical albuminuria. The urine is “dipstick positive,” containing more than 300 mg of albumin in a 24-hour period. Hypertension (high blood pressure) typically develops during stage 3.

Stage 4

(Overt-proteinuria Hypertension (Progressive sclerosis) late-stage diabetes)—Glomerular damage continues, with increasing amounts of protein albumin in the urine. The kidneys’ filtering ability has begun to decline steadily, and Blood Urea Nitrogen (BUN) and Creatinine (Cr) has begun to increase. The Glomerular Filtration Rate (GFR) decreases about 10% annually. Almost all patients have hypertension at stage 4.

Stage 5

ESRD (Fibrosis/sclerosis) GFR has fallen to approximately 10 milliliters per minute (<10 mL/min) and renal replacement therapy (i.e., hemodialysis, peritoneal dialysis, kidney transplantation) is needed [6].

Pathogenesis of Diabetic Nephropathy

Various pathways like polyol pathway, formation of advanced glycation end products [7], hexosamine pathway [8], protein kinase C pathway [9], growth factors, cytokines [10] and free radicals [11], MAPK activation, PARP activation have been reported to play an important role in diabetic nephropathy.

*Corresponding author: Virvikram Sharma, Department of Pharmacology, Isf College of Pharmacy b-1,665/19d, New Kundan Puri, Civil Lines, Ludhiana, India 141001, India; Fax: +91-1636-236564; Tel: 919878903414; E-mail: virvikram76@gmail.com

Received February 05, 2013; Accepted April 28, 2013; Published May 04, 2013

Citation: Sharma V, Sharma PL (2013) Role of Different Molecular Pathways in the Development of Diabetes-Induced Nephropathy. J Diabetes Metab S9: 004. doi:10.4172/2155-6156.S9-004

Copyright: © 2013 Sharma V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Polyl pathway

The polyol pathway consists of two enzymes. The first enzyme, Aldose Reductase (AR), reduces glucose to sorbitol with the aid of its co-factor NADPH, and the second enzyme, sorbitol dehydrogenase (SDH), with its co-factor NAD+, converts sorbitol to fructose, a process that increases the ratio of NADH/NAD and may result in both oxidative stress and activation of protein kinase C [12]. Fructose and its metabolites fructose-3-phosphate and 3-deoxyglucose are more potent nonenzymatic glycation agents than glucose. Sorbitol may interfere with the uptake and metabolism of myo-inositol [13]. The physiological role of the AR pathway remains largely unknown. However, AR, sorbitol and myo-inositol are thought to play a role in the osmoregulation of the kidney [14]. Consumption of NADPH by AR results in the depletion of the levels of NADPH. This NADPH also acts as a cofactor for glutathione reductase, which reduces oxidized glutathione into reduced glutathione [2]. Excess sorbitol is oxidized to fructose. The flux of glucose through the polyol pathway would increase Glycation End Products (AGE) formation. AGEs, as well as binding of AGE to their receptors, are known to cause oxidative stress [15].

Age pathways

AGEs accumulate at site of microvascular injury in diabetes, including the kidney [16], the retina and within the vasculature [17]. Their importance as downstream mediators of tissue injury in diabetic kidney disease is demonstrated by animal studies using inhibitors of advanced glycation to retard the development of nephropathy without directly influencing glycemic control [18].

AGE receptors are present on various renal cell types including proximal tubular cells, mesangial cells, and podocytes [19]. AGE promote activation and expression of IL-6 and TGFβ1 via NF-κB-dependent pathways [20]. The proximal tubule is the main site for reabsorption of filtered AGEs [21]. TGF-β1 expression is closely linked to accumulation of AGEs in the kidney [22]. AGEs are thought to lead to the transcriptional up-regulation of TGF-β1, possibly via PKC or oxidative stress. In experimental diabetes, oxidative stress is increased in proportion to the accumulation of AGEs [23]. AGEs can also lead to enhanced formation of free radicals both directly through catalytic sites in their molecular structure [24] and via stimulation of membrane bound NAD(P)H oxidase through the RAGE receptor and depletion of cellular antioxidant systems, such as glutathione peroxidase [25]. Mitochondrial dysfunction induced by AGEs and carbonyl intermediates may also contribute to the generation of superoxide [26]. AGE contribute to the release of proinflammatory cytokine and expression of growth factor and adhesion molecule such as VEGF and CTGF, TGF-β1, IGF-1, PDGF, TNF-a, IL-1β, and IL-6 [20,27].

Protein kinase C pathway

PKC has eleven isoforms. Nine PKCs are activated by DAG, which is formed from excess glycerolaldehyde-3-phosphate. Increased glucose concentration results in increase amount of DAG, which activates PKC. PKC activation leads to changes in renal blood flow [28], by decreasing production of NO [29], mesangial expansion, albuminuria and increases GFR, increases pro-inflammatory gene expression and vascular permeability in several models of experimental diabetes [30]. PKC activation may be responsible for the increased expression of ECM molecules both directly and through TGF-β1 overexpression. The capacity of active PKC to induce the formation of the transcription factor AP-1 is believed to be the major underlying mechanism of this combined induction of TGF-β1 and ECM protein genes. In the glomeruli, DAG levels are increased and PKC is activated [31]. Downstream of DAG-sensitive PKC isoforms is their activation of mitogen activated protein kinases (ERK) 1/2, which are essential for mesangial cell growth and enhanced gene expression, including growth factors and extracellular matrix proteins [32]. ERK1/2 protein expression is unchanged but its activity is significantly increased through PKC dependent manner in mesangial cell and glomeruli. ET-1 stimulated collagen IV expression is also dependent on the activation of ERK1/2 through PKC activation [33].

Hexosamine Pathway

The hexosamine converts fructose-6-phosphate into glucosamine-6-phosphate. Glutamine: Fructose-6-Phosphatamidotransferase (GFAT) is the rate-limiting enzyme of this pathway. Both high glucose and Ang II activates the GFAT promoter in mesangial cells [34] and this is a further mechanism that may enhance flux through the hexosamine. Overexpression of GFAT in MC leads to enhanced both TGF-β and fibronectin expression [35]. Furthermore, high glucose-induced TGF-β1 and ECM production appear, at least in part, mediated by the hexosamine because they are significantly reduced by the GFAT inhibitor azaresine [36]. The mechanism by which increased flux through the HBSP induced gene transcription is uncertain, but it has been proposed that N-acetylglucosamine may covalently modify transcription factors and signalling molecules, thus altering their activity. An increased flux through this path-way is associated with PKC activation, increased TGF-β expression and ECM production, all of which are associated with the development of DN [37]. In addition, TGF-β closely interacts with the RAS and PKC activity and their interplay could be central in the development of DN [38].

Activation of Janus kinase (JAK)/STAT Pathway by Reactive Oxygen Species

High glucose enhances ANG II induced activation of the JAK/STAT pathway [39]. The JAK proteins are a family of cytosolic tyrosine kinases, which originally were thought to be coupled exclusively to cytokine receptors, such as those for the interleukins and interferons. The family contains four members (JAK1, JAK2, JAK3, and TYK2). In response to ligand binding to cytokine receptors, these JAK tyrosine kinases associate with, tyrosine-phosphorylate, and activate the cytokine receptor itself. Once activated, JAKs also tyrosines-phosphorylates and activate other signaling molecules, including the STAT family of nuclear transcription factors after binding of the STATs to the receptor [40]. Thus the JAK/STAT pathway is an important link between cell surface receptors and nuclear transcriptional events leading to cell growth. The mechanism(s) by which high glucose promotes JAK2 activation may be related to activation of JAK2 by ROS, and ROS are induced by high glucose in glomerular mesangial cells. It has shown that ROS stimulate the activity of JAK2 in fibroblasts. It have been shown that high glucose, via the polyol pathway, induces a rapid increase in intracellular ROS, such as H₂O₂ and O₂⁻, which can then act as signaling mediators in the activation of downstream mitogenic pathways, such as the JAK/STAT cascade [42]. It has been shown that high glucose, via the polyol pathway, induces a rapid increase in intracellular ROS, such as H₂O₂, which stimulates intracellular signaling events similar to those activated by ANG II, including phosphorylation of growth promoting kinases such as JAK2 [43].
NADPH Oxidase in Diabetic Nephropathy

NADPH is formed during glycolysis or oxidative phosphorylation and exerts antioxidant activity by regenerating glutathione [44]. Glutathione act as important intracellular antioxidant by reacting with ROS and organic peroxides [45]. Thus antioxidant defense system will reduce with the reduction in the level of NADPH. In renal vessels, the macula densa, thick ascending limb of loop of Henle, distal tubules, collecting ducts, interstitial fibroblasts and un glomerular podocyte and mesangial cells, the enzyme NADPH oxidase is a significant source of production of superoxide radical. For activation of NADPH oxidase, assembly of the subunits and translocation of p47phox to the membrane is necessary. NADPH oxidase generated superoxide radicals can react with NO forming peroxynitrite, which is a potent oxidant and nitrosylating agent. Furthermore, this reaction can cause NO deficiency. NO normally regulates tubuloglomerular feedback and renal blood flow, and is involved in regulation of natriuresis. The NO deficiency can be worsened by the fact that oxidative stress promotes activation of vasoconstrictors. Thus, NO deficient animal models develop glomerulosclerosis and proteinuria, as well as hypertension and renal failure [46]. Expression of p47phox is increased in podocytes, glomeruli, cortical distal tubules, loop of Henle and medullary collecting ducts in diabetic rats [47]. Further NADPH oxidase inhibitor, apocynin decreases the expression of gp91phox and activation of p47phox in diabetic rats [48]. Furthermore, increased NADPH oxidase activity will decrease NADPH/NADP+ ratio, causing oxidative stress by the TCA cycle enzyme complex a-ketoglutarate dehydrogenase [49]. However, NOX 4 expression was found abundantly in distal tubular cells [50]. High glucose or free fatty acid [51], oxidized LDL, hyperlipidemia [52], AngII in mesangial cell and endothelial cells are the potent activators of NADOH oxidase. Further, activation of NADPH oxidase causes an increase in ROS production. Furthermore, increased superoxide produced within the glomerular microcirculation decreases NO bioactivity on mesangial contraction and arteriolar tone and may contribute to many of the renal hemodynamic and vascular abnormalities in diabetic nephropathy [53].

Growth Factors and Cytokines

Several growth factors, cytokines, chemokines and vasoactive agents have been implicated in pathogenesis of diabetic nephropathy. TGF-β, a fibrotic cytokine, plays a central role in the development of renal hypertrophy and accumulation of ECM components [54]. In addition, there is increased infiltration of monocytes and macrophages into glomeuli early in diabetes. The release of growth factors and cytokines from these monocytes and macrophages (interlukin-8, monocyte chemotactic peptide-1 etc.) may contribute to promotion of glomerular growth.

There is increasing evidence that intrarenal renin-angiotensin system is activated in diabetic nephropathy [55]. There is enhanced expression of Ang II receptors and deceased degradation of Ang II thereby increasing the local effects of Ang II [56] which acts in synergy with hyperglycemia in stimulating free radicals, renal hypertrophy and synthesis of ECM proteins. Other growth factors which are involved in the development of diabetic nephropathy are Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Connective Tissue Growth Factor (CTGF), and Insulin-Like Growth Factor (IGF) [57].

VEGF in Diabetic Nephropathy

Vascular Endothelial Growth Factor (VEGF) is an attractive candidate to function as a mediator of endothelial dysfunction in diabetes. Under physiological conditions, VEGF is produced in kidney by glomerular epithelial cells, but mesangial and tubular epithelial cells do not normally produce this growth factor. It was demonstrated that during hyperglycemia, overexpression of VEGF occurs through PKC activation [58]. Further, TGF-β1 which is over expressed in kidney also enhances VEGF expression [59]. Moreover, glomerular permeabilization by VEGF might induce both albuminuria and increased mesangial traffic of growth factors from the circulating blood. Hyperglycaemia increases VEGF excretion in the mesangial cell and podocyte via pathways involving PKC and extracellular signal-regulated kinase (ERK) [60]. Receptors for VEGF in the glomerulus are found in the endothelial cells and it is thought that this growth factor increases the permeability of the glomerular endothelium and is therefore responsible for the hyperfiltration seen in early diabetic nephropathy. Also mechanical stretch mimicking the shear stress caused by hyperfiltration and increased glomerular pressure increased the excretion of VEGF in the mesangial cells. In a study demonstrating this effect it seemed that the effects of shear stress in mesangial cells are mediated via a pathway dependent on PKC and Protein Tyrosine Kinase (PTK) since the combined inhibition of these enzymes completely prevented the increased VEGF excretion in an in vitro experiment [61]. However, MC can also produce VEGF [62] and express VEGF receptors both in vitro and in pathological conditions [63]. Furthermore, VEGF binding to its receptors on MC induces both cell proliferation and collagen expression, providing a possible mechanism by which VEGF may contribute to glomerular hypertrophy/sclerosis [64]. In addition, VEGF potentially stimulate eNOS expression and activity in endothelial cells [65].

TGF-β1 in Diabetic Nephropathy

The TGF-β seems to play a central role as a mediator in the pathologic changes in the glomerulus. It has been shown that the AGE formation, PKC activation, angiotensin II, and shear stress increase TGF-β expression [66]. TGF-β is a potent growth factor promoting the deposition of ECM components, such as collagen I, IV and fibronectin. This leads to, the histologically evident glomerular expansion and thickening of the basement membrane. The effects of TGF-β are mediated by the TGF-β receptor type II [67], while the Smad pathway is the downstream intracellular signaling pathway involved in TGF-β signaling [68]. This cytokine play a central role in the development of renal hypertrophy and accumulation of ECM components in diabetes [69]. During hyperglycemia, mesangial and proximal tubular cells synthesise more TGF-β than control [70]. In addition, it has been demonstrated that intracellular glucosamine production resulting from glucose metabolism is responsible for the increased TGF-β1 production in mesangial cells. Several vasoactive factors such as AngII, thromboxane [71] & endothelin-1 [72] may exert part of their growth-stimulating and profibrogenic action in diabetic renal diseases to the secondary induction of TGF-β. Furthermore non-enzymatic glycation reactions leading to AGE [73], as well as the early Amadori glucose adducts in proteins such as serum albumin have [74] been shown to stimulate renal expression of TGF-β. Amadori glucose adducts in albumin also increase expression of TGF-β type II receptors m-RNA and protein levels in mesangial cells [75].

PDGF in Diabetic Nephropathy

The platelet derived growth factor beta (PDGF-β) is also involved in the histological alterations in the glomerulus. Under high glucose concentrations the PDGF-β growth factor and the corresponding
receptor are upregulated in the mesangial cell leading to later increase in TGF-β expression [76].

**Role of Oxidative Stress in Diabetic Nephropathy**

Hyperglycemia-induced oxidative stress has been suggested as the unifying mechanism causing the cell damage seen in diabetic complications [2]. Oxidative stress plays an important role in pathological changes of the kidney [77]. Oxidative stress occurs due to an imbalance between Reactive Oxygen Species (ROS) and intracellular antioxidants [78]. Further, it has been suggested that hyperglycemia

![Figure 1: Diabetic nephropathy.](image_url)
induced overproduction of superoxide by mitochondrial electron transfer chain is the major molecular mechanisms for diabetes. Furthermore, increased NADPH oxidase activity leads to production of ROS in diabetic nephropathy [45]. Moreover, activation of PKC pathway leads to the production of ROS in diabetes which is attenuated by PKC inhibitors. In addition, it has been reported that, ROS activates (PKC, MAPK, JAK/STAT) and transcription factors (NF-kb, AP-1 and SP-1) and upregulates TGF-β1 and fibronectin levels leading to accumulation of ECM in diabetic kidney. The current understanding is about the nonphagocyte NADPH oxidase at both structural and biochemical levels and the possible role in diabetic nephropathy. It has been demonstrated that PKC is actively involved in high glucose and free fatty acid-induced activation of NADPH oxidase [45]. High glucose, free fatty acid and phorbol ester-induced ROS generation was effectively inhibited by PKC inhibitors. Evidences suggested that ROS-regulated signaling pathways lead to Extracellular Matrix (ECM) deposition in diabetic kidney. ROS generated by high glucose levels activate signal transduction cascade (PKC, MAPK, and JAK/STAT) and transcription factors (NF-kb, AP-1, and Sp1) and upregulate TGF-β1 and fibronectin in renal cells, and antioxidants effectively inhibit high glucose induced activation. It has been demonstrated that, in addition to upregulation of ECM synthesis, ROS play an important role in ECM degradation and epithelial-mesenchymal transition in tubular epithelial cells leading to glomerular mesangial and tubulointerstitial expansion [79]. It has been demonstrated that dichlororfluorescein sensitive ROS are increased in the glomeruli isolated from streptozotocin-diabetic rats, providing a direct evidence of increased ROS in diabetic glomeruli [41]. AGE are known to have a wide range of chemical, cellular, and tissue effects implicated in the development and progression of diabetic nephropathy. AGE generate ROS directly or through receptor for AGE, whereas ROS, in turn, promote formation of AGE. It has been demonstrated that AGE play an important role in diabetic nephropathy [80]. It has been demonstrated that over expression of receptor r for AGE (RAGE) exaggerates nephropathy and retinopathy of diabetic mice, which are inhibited by inhibition of AGE formation. Antioxidant effectively inhibit high glucose induced TGF-β1 and fibronectin upregulation [81] and reduces the oxidative stress by increasing the levels of intracellular antioxidants such as superoxide dismutase, catalase etc (Figure 1).

Mitochondrial Electron Transport System (ETS)

The mitochondrial ETS has long been known to be capable of generating ROS up to 2% of the total mitochondrial O₂ consumption goes towards the production of ROS [82]. The specific species generated appear to be O²⁻ following its dismutation, H₂O₂. The production of ROS by mitochondria can involve NADH-coenzyme Q (complex I), succinate-coenzyme Q (complex II) and coenzyme Q H⁻ cytochrome c reductases (complex III). A nonheme Fe⁺ protein appear to be involved in the transfer of electrons to oxygen at each site. Most of this transfer is tightly coupled but a small amount of leakage occurs, primarily from NADH-coenzyme Q reductase complex and from autoxidation of coenzyme Q itself. Ubisemiquinone and ubiquinol have been proposed as the main sources of mitochondrial O²⁻ by participating in auto-oxidation reaction [83]. When the electrochemical potential difference generated by the proton gradient is high (such as in high glucose states), the life of superoxide-generating electron transport intermediates, such as ubisemiquinone, is prolonged. This occurs because the activity of the respiratory chain complexes as proton pumps is inherently governed by the transmembrane proton gradient (ΔpH) and the membrane potential (ΔΨmt). When sufficiently high, ΔpH and ΔΨmt inhibit the proton pumps [84]. It is evident that each of the ROS-generating sites has a different redox potential, and thus each will respond differently to changes in ΔpH and ΔΨmt, resulting in a complex regulation of ROS generation by these membrane gradients. There appears to be a threshold value above which even a small increase in ΔΨmt gives rise to a large stimulation of superoxide production by mitochondria [85]. Overall, most bioenergetic effectors, via their effects on ΔpH and ΔΨmt, can modulate mitochondrial ROS generation. In isolated mitochondria, dissipation of membrane potential by chemical uncouplers, free fatty acids, or the presence of ADP decreases the rate of ROS generation.

Uncoupling Proteins (UCPs) are members of a family of nuclear-encoded mitochondrial carriers, which act as proton carrier proteins in the mitochondrial inner membrane. Further, these proteins facilitate the proton leak across the membrane and able to modulate the coupling between the respiratory electron transport chain and ATP synthesis. Furthermore, UCP-induced proton leakiness causes partial depolarization of the mitochondrial transmembrane potential [86]. However, the UCP subtypes, UCP-1, UCP-2, and UCP-3, differ with respect to tissue distribution and probably also function. Increased induction of UCP-1 leads to thermogenesis. However, the functions of UCP-2 and UCP-3 are still unclear but are believed to cause a mild uncoupling of respiration that governs mitochondrial membrane potential and the accumulation of oxygen radicals and/or control of the NAD⁺/NADH ratio. It has been demonstrated that UCP-2 expression is inversely correlated with the level of ROS generation by respiring mitochondria [87]. During diabetes, overexpression of UCPs in cultured neurons blocks glucose-induced programmed cell death by preventing mitochondrial hyperpolarization and formation of ROS. This suggests a central role for UCPs in the regulation of mitochondrial membrane hyperpolarization and ROS formation in glucose-mediated neuronal injury.

Acknowledgments

I am highly thankful to Prof. P.L. Sharma for his critical review, remarks, and suggested corrections in the paper.

References

1. Ohashi N, Urushihara M, Satou R, Kobori H (2010) Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species—ERK/ JNK pathways. Hypertens Res 33: 1174-1181.
2. Alter ML, Ott IM, von Websky K, Tsyprykov O, Sharkovska Y, et al. (2012) DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 36: 119-130.
3. Jankun J (2012) Challenging delivery of VLHL NS plasminogen activator inhibitor-1 by osmotic pumps in diabetic mouse: A case report. Exp Ther Med 4: 661-664.
4. Hao HH, Shao ZM, Tang DQ, Lu Q, Chen X, et al. (2012) Preventive effects of rutin on the development of experimental diabetic nephropathy in rats. Life Sci 91: 959-967.
5. Bonventre JV (2012) Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol 32: 452-462.
6. Romesh Khondari (2000) Non-renal replacement modalities in treatment of diabetic nephropathy. Int J Diab Dev Countries 20: 127-132.
7. Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, et al. (2012) Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltransferase-1 expression. Am J Pathol 182: 132-141.
8. Riedl E, Pfister F, Braunagel M, Brinkkötter P, Sternik P, et al. (2011) Carnosine prevents apoptosis of glomerular cells and podocyte loss in STZ diabetic rats. Cell Physiol Biochem 28: 279-288.
Citation: Sharma V, Sharma PL (2013) Role of Different Molecular Pathways in the Development of Diabetes-Induced Nephropathy. J Diabetes Metab 5: 104. doi:10.4172/2155-6156.59-004

Page 6 of 7
Insights from cell culture studies and animal models. *Knee Blood Press Res* 22: 81-97.

71. Osaki T, Azuma K, Kurozumi S, Takamori Y, Tsuka T, et al. (2012) Metabolomic analyses of blood plasma after oral administration of D-glucosamine hydrochloride to dogs. *Mar Drugs* 10: 1873-1882.

72. Hu Z, Ren L, Wang C, Liu B, Song G (2012) Effect of chenodeoxycholic acid on fibrosis, inflammation and oxidative stress in kidney in high-fructose-fed Wistar rats. *Knee Blood Press Res* 36: 85-97.

73. Jung DH, Kim YS, Kim NH, Lee J, Jang DS, et al. (2010) Extract of Cassiae Semen and its major compound inhibit S100β-induced TGF-beta1 and fibronectin expression in mouse glomerular mesangial cells. *Eur J Pharmacol* 641: T-14.

74. Li Q, Ye F, Shi Y, Zhang L, Wang W, et al. (2006) Nuclear translocation of SMAD3 may enhance the TGF-beta/SMAD pathway in high glucose circumstances. *Transplant Proc* 38: 2158-2160.

75. Wahab NA, Schaefer L, Weston BS, Yaniokouris O, Wright A, et al. (2005) Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interrelated roles in mesangial response to diabetic stimuli. *Diabetologia* 48: 2650-2660.

76. Zou L, Wang W, Xu Z, Zhang N, Jiang T (2012) Aldose reductase regulates platelet-derived growth factor-induced proliferation through mediating cell cycle progression in rat mesangial cells. *Int J Mol Med* 30: 409-416.

77. Fang D, Wan X, Deng W, Guan H, Ke W, et al. (2012) Fufang Xue Shuan Tong capsules inhibit renal oxidative stress markers and indices of nephropathy in diabetic rats. *Exp Ther Med* 4: 871-876.

78. Palacios HH, Yenduri BB, Parvathenani K, Shadlinski VB, Obrenovich ME, et al. (2011) Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease. *CNS Neuropl Disord Drug Targets* 10: 149-162.

79. Bai S, Zeng R, Zhou G, Liao W, Zhang Y, et al. (2012) CdO42-interacting protein-4 promotes TGF-β1-induced epithelial-mesenchymal transition and extracellular matrix deposition in renal proximal tubular epithelial cells. *Int J Biol Sci* 8: 859-869.

80. Lal YL, Aycama S, Ohata M, Otsuka N, Shiokawa H, et al. (2012) Dysregulation of dimethylargininedimethylaminohydrolase/asymmetric dimethylarginine pathway in rat type II diabetic nephropathy. *J Clin Biochem Nutr* 51: 143-149.

81. Lin T, He F, Lei B (2012) [Expressions of adiponectin and its receptors in the retina of normal and type 1 diabetic mice]. Nan Fang Yi Ke Da Xue Xue Bao 32: 1543-1547.

82. Yang CA, Cheng CH, Lee JW, Lo CT, Liu SY, et al. (2012) Monoceramic L-amino acid oxidase-induced mitochondrial dysfunction in Rhizodoma solani Reveals a novel antagonistic mechanism of Trichoderma harzianum ETS 323. *J Agric Food Chem* 60: 2464-2471.

83. Samolova RI, Crofts AR, Dikanov SA (2011) Reaction of superoxide radical with quinoline molecules. *J Phys Chem A* 115: 11589-11593.

84. Nguyen TT, Ogbi M, Yu Q, Johnson JA (2010) Attenuation of the hypoxia-induced protein kinase Cdelta interaction with the ‘δ’ subunit of F1Fo-ATP synthase in neonatal cardiac myocytes: implications for energy preservation and survival. *Biochim Biophys Acta* 429: 335-345.

85. Hashem FM, Shaker DS, Nasr M, Saad IE, Ragaye R (2011) Guar gum and hydroxy propyl methylcellulose compressed coated tablets for colonic drug delivery: in vitro and in vivo evaluation in healthy human volunteers. *Drug Discov Ther* 5: 90-95.

86. Berardi MJ, Shih WM, Harrison SC, Chou JJ (2011) Mitochondrial uncoupling protein 2 structure determined by NMR molecular fragment searching. *Nature* 476: 129-133.

87. Qian S, Hu D, Wang S, Qian Q (2011) Inhibition of glucose-induced vascular endothelial growth factor expression by Salvia miltiorrhiza hydrophilic extract in human microvascular endothelial cells: evidence for mitochondrial oxidative stress. *J Ethnopharmacol* 137: 985-991.